References
- Orkin C, Llibre JM, Gallien S, et al. Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence. HIV Med. 2018;19(1):18–32.
- Richman D, Whitley RJ, Hayden FG. Clinical Virology. 4th ed. Washington, DC: ASM Press; 2017.
- Bocanegra R, Rodriguez-Huete A, Fuertes MA, et al. Molecular recognition in the human immunodeficiency virus capsid and antiviral design. Virus Res. 2012;169(2):388–410.
- Fassati A. Multiple roles of the capsid protein in the early steps of HIV-1 infection. Virus Res. 2012;170(1–2):15–24.
- Forshey BM, von Schwedler U, Sundquist WI, et al. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol. 2002;76(11):5667–5677.
- Pertel T, Hausmann S, Morger D, et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature. 2011;472(7343):361–365.
- Li G, Verheyen J, Rhee SY, et al. Functional conservation of HIV-1 Gag: implications for rational drug design. Retrovirology. 2013;10:126.
- Tang C, Loeliger E, Kinde I, et al. Antiviral inhibition of the HIV-1 capsid protein. J Mol Biol. 2003;327(5):1013–1020.
- Pornillos O, Ganser-Pornillos BK, Kelly BN, et al. X-ray structures of the hexameric building block of the HIV capsid. Cell. 2009;137(7):1282–1292.
- Lamorte L, Titolo S, Lemke CT, et al. Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes. Antimicrob Agents Chemother. 2013;57(10):4622–4631.
- Blair WS, Pickford C, Irving SL, et al. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog. 2010;6(12):e1001220.
- Tse WC, Link JO, Mulato A. et al. Discovery of novel potent HIV capsid inhibitors with long- acting potential. Conference on Retroviruses and Opportunistic Infections, Seattle, Washington; 2017.
- Perrier M, Bertine M, Le Hingrat Q, et al. Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients. J Antimicrob Chemother. 2017;72(10):2954–2955.
- Yant SR, Mulato A, Stepan G. et al. GS-6207, a potent and selective first-in-class long-acting HIV-1 capsid inhibitor. Conference on Retroviruses and Opportunistic Infections, Seattle, Washington; 2019.
- Yant SR, Mulato A, Hansen D. et al. In vitro resistance profile of GS-6207, a first-in-class picomolar HIV capsid inhibitor in clinical development as a novel long-acting antiretroviral agent. International AIDS Conference. Mexico; 2019.
- Jennifer E, Sager RB, Rhee M. et al. Safety and pk of subcutaneous GS-6207, a novel HIV-1 capsid inhibitor. Conference on Retroviruses and Opportunistic Infections,Seattle, Washington; 2019.
- Daar ES, McDonald C., Crofoot G. et al. Safety and antiviral activity over 10 days following a single dose of subcutaneous GS-6207, a first-in-class, long-acting HIV capsid inhibitor in people living with HIV. International AIDS Conference, Mexico; 2019.